Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Clinical drug investigation

• Publication date

  2019-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40261-018-00746-5PMID 30778885
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer

  2018cited by this paper
• Cancer statistics, 2018

  2018cited by this paper
• Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

  2018cited by this paper
• Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

  2018cited by this paper
• Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.

  2018cited by this paper
• Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

  2018cited by this paper
• Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

  2018cited by this paper
• Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

  2018cited by this paper
• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

  2018cited by this paper
• Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade

  2018cited by this paper
• Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer

  2018cited by this paper
• An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer

  2018cited by this paper
• Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

  2018cited by this paper
• PD-1/PD-L1 Axis in Lung Cancer

  2018cited by this paper
• Combination Therapy of Radiotherapy and Anti‐PD‐1/PD‐L1 Treatment in Non–Small‐cell Lung Cancer: A Mini‐review

  2018cited by this paper
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?

  2017cited by this paper
• First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer

  2017cited by this paper
• Tim‐3 and its role in regulating anti‐tumor immunity

  2017cited by this paper
• Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

  2017cited by this paper
• Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

  2017cited by this paper
• Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

  2017cited by this paper
• Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

  2017cited by this paper
• Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

  2017cited by this paper
• VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

  2017cited by this paper
• PD-L1 IHC in NSCLC with a global and methodological perspective.

  2017cited by this paper
• Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cited by this paper
• The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

  2017cited by this paper
• Leading Edge Review Primary , Adaptive , and Acquired Resistance to Cancer Immunotherapy

  2017cited by this paper
• Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

  2017cited by this paper
• Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

  2017cited by this paper
• Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

  2017cited by this paper
• LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes

  2017cited by this paper
• Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy.

  2017cited by this paper
• Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy

  2017cited by this paper
• MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer

  2016cited by this paper
• Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O

  2016cited by this paper
• CTLA-4 and PD-1 Pathways

  2016cited by this paper
• HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status

  2016cited by this paper
• Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy

  2016cited by this paper
• Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

  2016cited by this paper
• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma.

  2015cited by this paper
• Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.

  2015cited by this paper
• Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy.

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Evolving synergistic combinations of targeted immunotherapies to combat cancer

  2015cited by this paper
• Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity.

  2014cited by this paper
• Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

  2014cited by this paper
• Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo

  2014cited by this paper
• Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues.

  2014cited by this paper
• VISTA Regulates the Development of Protective Antitumor Immunity.

  2014cited by this paper
• VISTA is an immune checkpoint molecule for human T cells.

  2014cited by this paper
• The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

  2014cited by this paper
• Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

  2014cited by this paper
• B7-H5 costimulates human T cells via CD28H

  2013cited by this paper
• Management of non-small-cell lung cancer: recent developments.

  2013cited by this paper
• HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

  2013cited by this paper
• An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer

  2013cited by this paper
• Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

  2012cited by this paper
• TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression

  2012cited by this paper
• Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion

  2012cited by this paper
• Bat3 Protects T cell Responses by Repressing Tim-3-Mediated Exhaustion and Death

  2012cited by this paper
• Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions

  2011cited by this paper
• Vstm3 is a member of the CD28 family and an important modulator of T‐cell function

  2011cited by this paper
• Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

  2010cited by this paper
• Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

  2010cited by this paper
• The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

  2009cited by this paper
• The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

  2009cited by this paper
• Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

  2007cited by this paper
• Current state of immunotherapy for non-small cell lung cancer.

  2007cited by this paper
• The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

  2005cited by this paper
• Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule

  2003cited by this paper
• Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31

  2002cited by this paper
• Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

  1999cited by this paper
• Molecular basis of T cell inactivation by CTLA-4.

  1998cited by this paper
• Cisplatin and carboplatin-mediated activation of murine peritoneal macrophages in vitro: production of interleukin-1 alpha and tumor necrosis factor-alpha.

  1995cited by this paper
• LAG-3, a novel lymphocyte activation gene closely related to CD4

  1990cited by this paper
• Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

  year unknowncited by this paper

• IL20RB as a prognostic and immune-related biomarker in lung cancer: association with immune infiltration, tumor progression, and potential therapeutic targeting

  2026cites this paper
• Interleukin 35 promotes progression of hepatocellular carcinoma by recruiting neutrophils

  2026cites this paper
• Lung Cancer Immunotherapy Approaches: From Clinical Testing to Future Advances

  2025cites this paper
• Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia

  2023cites this paper
• Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer

  2023cites this paper
• lncRNA CERS6-AS1 upregulates the expression of ANLN by sponging miR-424-5p to promote the progression and drug resistance of lung adenocarcinoma

  2023cites this paper
• YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

  2023cites this paper
• Serum Level of CEACAM1 in Patients with Nonsmall Cell Lung Cancer and Its Clinical Significance in Cancer Tissue

  2022cites this paper
• Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.

  2022cites this paper
• Constructing a Tregs-associated signature to predict the prognosis of colorectal cancer patients: A STROBE-compliant retrospective study

  2022cites this paper
• Improved cancer immunotherapy strategies by nanomedicine.

  2022cites this paper
• Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives

  2022cites this paper
• mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers

  2022cites this paper
• Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment

  2022cites this paper
• Functions and modulation of PKM2 activity by human papillomavirus E7 oncoprotein (Review)

  2022cites this paper
• Clinical Significance of PD-L1 Expression and CD8-Positive Tumor-Infiltrating Lymphocytes in Patients with Cavitary Lung Adenocarcinoma

  2021cites this paper
• Immunogenomic Gene Signature of Cell-Death Associated Genes with Prognostic Implications in Lung Cancer

  2021cites this paper
• RETRACTED: Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles

  2021cites this paper
• Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia

  2021cites this paper
• Mechanism of PKM2 affecting cancer immunity and metabolism in Tumor Microenvironment

  2021cites this paper
• Identification and Integrated Analysis of circRNA and miRNA of Radiation-Induced Lung Injury in a Mouse Model

  2021cites this paper
• Pan-Cancer Analysis Reveals FH as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma

  2021cites this paper
• High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma

  2020cites this paper
• High expression of PD-L1 Predicts Worse Overall Survival in the Cavitary Lung Adenocarcinoma

  2020influential citation
• Interleukin 35 Activates Intratumor Neovascularization Via Enhanced Secretion of FGF2 in Hepatocellular Carcinoma Through The Recruitment of Neutrophils, and Blocking it Could Facilitate The Efficacy of The PD-1 Antibody

  2020cites this paper
• Identi cation of immune prognostic signature of lung carcinoma based on Genome-wide immune expression pro le

  2020cites this paper
• Identification of immune prognostic signature of lung carcinoma based on Genome-wide immune expression profile

  2020cites this paper
• DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

  2020cites this paper
• CSF1R and HCST: Novel Candidate Biomarkers Predicting the Response to Immunotherapy in Non-Small Cell Lung Cancer

  2020cites this paper
• Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy

  2020cites this paper
• High-throughput untargeted metabolomics and chemometrics reveals pharmacological action and molecular mechanism of chuanxiong by ultra performance liquid chromatography combined with quadrupole-time-of-flight-mass spectrometry

  2019cites this paper
• Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

  2019cites this paper
• Twenty-four-color full spectrum fl ow cytometry panel for minimal residual disease detection in acute myeloid leukemia

  year unknowncites this paper